Advanced search
Publication Cover
Expert Review of Molecular Diagnostics Volume 16, 2016 - Issue 2
Submit an article Journal homepage
1,374
Views
78
CrossRef citations to date
0
Altmetric
Technology Report

Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution

Nikolas H. StoeckleinDepartment of General, Visceral and Pediatric Surgery, Medical Faculty, University Hospital of the Heinrich-Heine-University Düsseldorf, Düsseldorf, GermanyCorrespondence[email protected]
,
Johannes C. FischerInstitute for Transplantation Diagnostics and Cell Therapeutics, Medical Faculty, University Hospital of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
,
Dieter NiederacherDepartment of Obstetrics and Gynecology, Medical Faculty, University Hospital of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
&
Leon W. M. M. TerstappenDepartment of Medical Cell BioPhysics, MIRA Institute, University of Twente, Enschede, The Netherlands
Pages 147-164 | Received 24 Jul 2015, Accepted 18 Nov 2015, Published online: 16 Dec 2015

References

  • Papers of special note have been highlighted as:
  • • of interest
  • •• of considerable interest
  • Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010;70(14):5649–5669.
  • Sleeman JP, Nazarenko I, Thiele W. Do all roads lead to Rome? Routes to metastasis development. Int J Cancer. 2011;128(11):2511–2526.
  • Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–1558.
  • Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2015;7(1):1–11.
  • Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. 2015. DOI:10.1038/onc.2015.192. [Epub ahead of print]
  • Barradas AMC, Terstappen LWMM. Towards the biological understanding of CTC: capture technologies, definitions and potential to create metastasis. Cancers (Basel). 2013;5(4):1619–1642.
  • Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29(12):1556–1563.
  • Pool EH, Dunlop GR. Cancer cells in the blood stream. Cancer Res. 1934;21(1):99–102.
  • Moore GE, Sandberg A, Schubarg JR. Clinical and experimental observations of the occurrence and fate of tumor cells in the blood stream. Ann Surg. 1957;146(4):580–587.
  • Engell HC. Cancer cells in the circulating blood; a clinical study on the occurrence of cancer cells in the peripheral blood and in venous blood draining the tumour area at operation. Acta Chir Scand Suppl. 1955;201:1–70.
  • Roberts S, Jonasson O, Long L, et al. Clinical significance of cancer cells in the circulating blood: two- to five-year survival. Ann Surg. 1961;154:362–371.
  • Economou SG, Mrazek R, Cole WH. Adjunctive cancer chemotherapy in surgery of the colon and rectum. Dis Colon Rectum. 1958;1(6):424–431.
  • Fisher B, Ravdin RG, Ausman RK, et al. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg. 1968;168(3):337–356.
  • DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643–8653.
  • Coumans FAW, Ligthart ST, Uhr JW, et al. Challenges in the enumeration and phenotyping of CTC. Clin Cancer Res. 2012;18(20):5711–5718.

•• Based on modeling of extensive CS CTC data, this study demonstrated that larger volumes need to be investigated to increase CTC detection probability and predicted that 99% of patients had at least one CTC before therapy initiation if 5 L would be inspected.

  • Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10(20):6897–6904.

•• Initial paper describing the performance of the CS system.

  • Nieva J, Wendel M, Luttgen MS, et al. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Phys Biol. 2012;9(1):016004–17.
  • Karabacak NM, Spuhler PS, Fachin F, et al. Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc. 2014;9(3):694–710.
  • Vona G, Estepa L, Béroud C, et al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology. 2004;39(3):792–797.
  • Coumans FAW, van Dalum G, Beck M, et al. Filter characteristics influencing circulating tumor cell enrichment from whole blood. PLoS ONE. 2013;8(4):e61770.
  • Racila E, Euhus D, Weiss AJ, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA. 1998;95(8):4589–4594.
  • Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235–1239.
  • Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345(6193):216–220.
  • Rao CG, Chianese D, Doyle GV, et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol. 2005;27(1):49–57.
  • Lee RG, Bithell TC, Foerster J, et al. Winton’s clinical hematology. 9th ed. Philadelphia (PA): Lea & Febinger; 1993.
  • GE Healthcare Life Sciences. Cell separation media. Available from: http://www.gelifesciences.com/file_source/GELS/Service%20and%20Support/Documents%20and%20Downloads/Handbooks/pdfs/Cell%20Separation%20Media.pdf.
  • Ozkumur E, Shah AM, Ciciliano JC, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013;5(179):179ra47–179ra47.
  • Hofman VJ, Ilie MI, Bonnetaud C, et al. Cytopathologic detection of circulating tumor cells using the isolation by size of epithelial tumor cell method: promises and pitfalls. Am J Clin Pathol. 2011;135(1):146–156.
  • Fehm T, Sagalowsky A, Clifford E, et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res. 2002;8(7):2073–2084.
  • Swennenhuis JF, Tibbe AGJ, Levink R, et al. Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytometry A. 2009;75(6):520–527.
  • Breitenbuecher F, Hoffarth S, Worm K, et al. Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients. PLoS ONE. 2014;9(1):e85350–7.
  • Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem. 2011;57(9):1242–1255.
  • Müller V, Riethdorf S, Rack B, et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res. 2012;14(4):R118.
  • Helo P, Cronin AM, Danila DC, et al. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem. 2009;55(4):765–773.
  • Mostert B, Sieuwerts AM, Kraan J, et al. Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. Ann Oncol. 2015;26(3):510–516.
  • Schneck H, Blassl C, Meier-Stiegen F, et al. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Mol Oncol. 2013;7(5):976–986.
  • Smirnov DA, Zweitzig DR, Foulk BW, et al. Global gene expression profiling of circulating tumor cells. Cancer Res. 2005;65(12):4993–4997.
  • Sieuwerts AM, Kraan J, Bolt-de Vries J, et al. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat. 2009;118(3):455–468.
  • Magbanua MJM, Melisko M, Roy R, et al. Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Cancer Res. 2013;73(23):7134–7143.
  • Swennenhuis JF, Reumers J, Thys K, et al. Efficiency of whole genome amplification of single circulating tumor cells enriched by CellSearch and sorted by FACS. Genome Med. 2013;5(11):106.
  • Neves RPL, Raba K, Schmidt O, et al. Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer. Clin Chem. 2014;60(10):1290–1297.
  • Gross HJ, Verwer B, Houck D, et al. Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10(−7). Proc Natl Acad Sci USA. 1995;92(2):537–541.
  • Moreno JG, O’Hara SM, Gross S, et al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology. 2001;58(3):386–392.
  • Riethdorf S, Fritsche H, Müller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007;13(3):920–928.
  • Ignatiadis M, Riethdorf S, Bidard F-C, et al. International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res. 2014;16(2):R43.
  • Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–791.
  • de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–6309.
  • Scher HI, Heller G, Molina A, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol. 2015;33(12):1348–1355.
  • Cohen SJ, Punt CJA, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213–3221.
  • Allard WJ, Terstappen LWMM. CCR 20th anniversary commentary: paving the way for circulating tumor cells. Clin Cancer Res. 2015;21(13):2883–2885.
  • Hiltermann TJN, Pore MM, van den Berg A, et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol. 2012;23(11):2937–2942.
  • Hou J-M, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012;30(5):525–532.
  • Hiraiwa K, Takeuchi H, Hasegawa H, et al. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol. 2008;15(11):3092–3100.
  • Gröbe A, Blessmann M, Hanken H, et al. Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity. Clin Cancer Res. 2014;20(2):425–433.
  • van Dalum G, van der Stam GJ, Tibbe AGJ, et al. Circulating tumor cells before and during follow-up after breast cancer surgery. Int J Oncol. 2015;46(1):407–413.
  • van Dalum G, Stam G-J, Scholten LFA, et al. Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int J Oncol. 2015;46(3):1361–1368.
  • Pantel K, Denève E, Nocca D, et al. Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 2012;58(5):936–940.
  • Klein CA. Cancer. The metastasis cascade. Science. 2008;321(5897):1785–1787.
  • Klein CA. Selection and adaptation during metastatic cancer progression. Nature. 2013;501(7467):365–372.
  • Rhim AD, Thege FI, Santana SM, et al. Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. Gastroenterology. 2014;146(3):647–651.
  • Liu MC. By the numbers: does circulating tumor cell enumeration have a role in metastatic breast cancer? J Clin Oncol. 2014;32(31):3479–3482.
  • Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014;32(31):3483–3489.
  • Beije N, Jager A, Sleijfer S. Circulating tumor cell enumeration by the CellSearch system: the clinician’s guide to breast cancer treatment? Cancer Treat Rev. 2015;41(2):144–150.
  • McInnes LM, Jacobson N, Redfern A, Dowling A, Thompson EW, Saunders CM. Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticity. Front Oncol. 2015;5(9814):42.
  • Fehm T, Müller V, Aktas B, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010;124(2):403–412.
  • Fehm T, Jäger W, Kraemer S, et al. Changes of serum HER2 status during clinical course of metastatic breast cancer patients. Anticancer Res. 2004;24(6):4205–4210.
  • Arapantoni-Dadioti P, Valavanis C, Gavressea T, et al. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases. J BUON. 2012;17(2):277–283.
  • Schramm A, Friedl TWP, Schochter F, et al. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Arch Gynecol Obstet. 2015;1–11. DOI:10.1007/s00404-015-3879-7
  • Janni W, Fehm T. DETECT III [Internet]. 2015. Available from: www.detect-studien.de.
  • Punnoose EA, Atwal SK, Spoerke JM, et al. Molecular biomarker analyses using circulating tumor cells. PLoS ONE. 2010;5(9):e12517.
  • Spizzo G, Fong D, Wurm M, et al. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol. 2011;64(5):415–420.
  • Sieuwerts AM, Kraan J, Bolt J, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009;101(1):61–66.
  • Gires O, Stoecklein NH. Dynamic EpCAM expression on circulating and disseminating tumor cells: causes and consequences. Cell Mol Life Sci. 2014;71(22):4393–4402.
  • Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339(6119):580–584.
  • Zhang L, Ridgway LD, Wetzel MD, et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med. 2013;5(180):180ra48–180ra48.
  • Steinert G, Schölch S, Niemietz T, et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res. 2014;74(6):1694–1704.
  • de Wit S, Dalum GV, Lenferink ATM, et al. The detection of EpCAM(+) and EpCAM(-) circulating tumor cells. Sci Rep. 2015;5:12270.
  • Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31(6):539–544.
  • Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 2014;20(8):897–903.
  • Pecot CV, Bischoff FZ, Mayer JA, et al. A novel platform for detection of CK+ and CK- CTCs. Cancer Discov. 2011;1(7):580–586.
  • Adams DL, Stefansson S, Haudenschild C, et al. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the cellsearch(®) CTC test. Cytometry A. 2015;87(2):137–144.
  • Thalgott M, Rack B, Maurer T, et al. Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol. 2013;139(5):755–763.
  • Pachmann K, Camara O, Kavallaris A, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol. 2008;26(8):1208–1215.
  • Lecharpentier A, Vielh P, Perez-Moreno P, et al. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer. 2011;105(9):1338–1341.
  • Stott SL, Hsu C-H, Tsukrov DI, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA. 2010;107(43):18392–18397.
  • Pierga J-Y, Bidard F-C, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 2008;14(21):7004–7010.
  • Lucci A, Hall CS, Lodhi AK, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012;13(7):688–695.
  • Franken B, de Groot MR, Mastboom WJ, et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012;14(5):R133.
  • Rack B, Schindlbeck C, Jückstock J, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014;106(5):dju066–dju066.
  • Tibbe AGJ, Miller MC, Terstappen LWMM. Statistical considerations for enumeration of circulating tumor cells. Cytometry. 2007;71A(3):154–162.

• Describes the statistics of the different process steps that are needed for the isolation and detection of CTCs.

• This study describes a model developed to estimate tumor size and CTC concentration before distant metastasis occur.

  • Griwatz C, Brandt B, Assmann G, et al. An immunological enrichment method for epithelial cells from peripheral blood. J Immunol Methods. 1995;183(2):251–265.
  • Shimoni A, Körbling M. Tumor cell contamination in re-infused stem cell autografts: does it have clinical significance? Crit Rev Oncol Hematol. 2002;41(2):241–250.
  • Choi S, Rajan SS, Trivedi MV. The incidence of tumor cell contamination of peripheral blood stem cells: a meta-analysis to evaluate the impact of mobilization regimens and the influence on outcomes in breast cancer patients. Acta Haematol. 2014;131(3):133–140.
  • Mego M, Gao H, Lee B-N, et al. Prognostic value of EMT-circulating tumor cells in metastatic breast cancer patients undergoing high-dose chemotherapy with autologous hematopoietic stem cell transplantation. J Cancer. 2012;3:369–380.
  • Müller AMS, Kohrt HEK, Cha S, et al. Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biol Blood Marrow Transplant. 2012;18(1):125–133.
  • Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood. 1993;82(9):2605–2610.
  • Passos-Coelho J, Ross AA, Davis JM, et al. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res. 1994;54(9):2366–2371.
  • Passos-Coelho JL, Ross AA, Kahn DJ, et al. Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol. 1996;14(9):2569.
  • Franklin WA, Shpall EJ, Archer P, et al. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat. 1996;41(1):1–13.
  • Mapara MY, Körner IJ, Hildebrandt M, et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood. 1997;89(1):337–344.
  • Glück S, Ross AA, Layton TJ, et al. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment. Biol Blood Marrow Transplant. 1997;3(6):316–323.
  • Schulze R, Schulze M, Wischnik A, et al. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients. Bone Marrow Transplant. 1997;19(12):1223–1228.
  • Naume B, Borgen E, Nesland JM, et al. Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Int J Cancer. 1998;78(5):556–560.
  • Cooper BW, Moss TJ, Ross AA, et al. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. J Clin Oncol. 1998;16(11):3509–3517.
  • Franklin WA, Glaspy J, Pflaumer SM, et al. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. Blood. 1999;94(1):340–347.
  • Krüger W, Tögel F, Kröger N, et al. Tumour cell detection in G-CSF mobilised stem cell harvests of patients with breast cancer. Med Oncol. 1999;16(1):17–22.
  • Stadtmauer EA, Tsai DE, Sickles CJ, et al. Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination. Med Oncol. 1999;16(4):279–288.
  • Voso MT, Hohaus S, Moos M, et al. Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. Br J Haematol. 1999;104(2):382–391.
  • Lin YS, Zhong XY, Hohaus S, et al. Detection of tumor cells in leukapheresis products from patients with breast cancer using immunocytochemical staining method. Arch Gynecol Obstet. 2000;263(3):119–125.
  • Negrin RS, Atkinson K, Leemhuis T, et al. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant. 2000;6(3):262–271.
  • Kröger N, Krüger W, Renges H, et al. Comparison of progenitor cell collection on day 4 or day 5 after steady-state stimulation with G-CSF alone in breast cancer patients: influence on CD34+ cell yield, subpopulation, and breast cancer cell contamination. J Hematother Stem Cell Res. 2000;9(1):111–117.
  • Pedrazzoli P, Lanza A, Battaglia M, et al. Negative immunomagnetic purging of peripheral blood stem cell harvests from breast carcinoma patients reduces tumor cell contamination while not affecting hematopoietic recovery. Cancer. 2000;88(12):2758–2765.
  • Umiel T, Prilutskaya M, Nguyen NH, et al. Breast tumor contamination of peripheral blood stem cell harvests: increased sensitivity of detection using immunomagnetic enrichment. J Hematother Stem Cell Res. 2000;9(6):895–904.
  • Burgess J, Mills B, Griffith M, et al. Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34(+) cells. Cytotherapy. 2001;3(4):285–294.
  • Solano C, Badia B, Lluch A, et al. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant. 2001;27(3):287–293.
  • Dal Cortivo L, Cottu PH, Lotz JP, et al. Residual tumor cell contamination in peripheral blood stem cells collections of 117 breast cancer patients evaluated by immunocytochemical technique. J Hematother Stem Cell Res. 2001;10(6):855–862.
  • Kim DH, Muto M, Kuwahara Y, et al. Array-based comparative genomic hybridization of circulating esophageal tumor cells. Oncol Rep. 2006;16(5):1053–1059.
  • Kasimir-Bauer S, Mayer S, Bojko P, et al. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy. Clin Cancer Res. 2001;7(6):1582–1589.
  • Krüger W, Kröger N, Tögel F, et al. Influence of preharvest tumor cell contamination in bone marrow or blood does not predict resultant tumor cell contamination of granulocyte colony-stimulating factor mobilized stem cells. J Hematother Stem Cell Res. 2001;10(2):303–307.
  • Preti RA, Lazarus HM, Winter J, et al. Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer. Cytotherapy. 2001;3(2):85–95.
  • Pecora AL, Lazarus HM, Jennis AA, et al. Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: predictors and clinical relevance. Biol Blood Marrow Transplant. 2002;8(10):536–543.
  • Patriarca F, Sacco C, Sperotto A, et al. Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy. Bone Marrow Transplant. 2003;31(9):789–794.
  • Syme R, Stewart D, Rodriguez-Galvez M, et al. Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT). Bone Marrow Transplant. 2003;32(3):307–311.
  • Viret F, Chabannon C, Sainty D, et al. Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy. Bone Marrow Transplant. 2003;32(11):1059–1064.
  • Nieto Y, Franklin WA, Jones RB, et al. Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. Biol Blood Marrow Transplant. 2004;10(6):415–425.
  • Ferrucci PF, Rabascio C, Gigli F, et al. A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer. Int J Oncol. 2007;30(4):955–962.
  • Arpaci F, Safali M, Ozet A, et al. The clinical significance of tumor cells in bone marrow or apheresis product and the efficacy of CD34 +selection and high-dose chemotherapy in patients with Stage III breast cancer. J Clin Apher. 2009;24(5):197–204.
  • Fischer JC, Niederacher D, Topp SA, et al. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci USA. 2013;110(41):16580–16585.

•• First paper describing the use of DLA in cancer patients.

  • Burgstaler EA. Blood component collection by apheresis. J Clin Apher. 2006;21(2):142–151.
  • Wiltbank TB, Giordano GF. The safety profile of automated collections: an analysis of more than 1 million collections. Transfusion. 2007;47(6):1002–1005.
  • Nitz U, Mohrmann S, Fischer J, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet. 2005;366(9501):1935–1944.
  • Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.
  • Eifler RL, Lind J, Falkenhagen D, et al. Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept. Cytometry. 2010;80B(2):100–111.
  • Saucedo-Zeni N, Mewes S, Niestroj R, et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol. 2012;41(4):1241–1250.
  • CANCER-ID. Available from: www.cancer-id.eu.
  • CTCTrap. Available from: www.utwente.nltnwctctrap.
  • Gasch C, Bauernhofer T, Pichler M, et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem. 2013;59(1):252–260.
  • Heitzer E, Auer M, Gasch C, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013;73(10):2965–2975.
  • Yang Y, Rho HS, Stevens M, et al. Microfluidic device for DNA amplification of single cancer cells isolated from whole blood by self-seeding microwells. Lab Chip. 2015;15(22):4331–4337.
  • Swennenhuis JF, Tibbe AGJ, Stevens M, et al. Self-seeding microwell chip for the isolation and characterization of single cells. Lab Chip. 2015;15(14):3039–3046.
  • Magbanua MJM, Sosa EV, Roy R, et al. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res. 2013;73(1):30–40.
  • Pestrin M, Salvianti F, Galardi F, et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol. 2015;9(4):749–757.
  • Peeters DJE, De Laere B, Van den Eynden GG, et al. Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br J Cancer. 2013;108(6):1358–1367.
  • Fernandez SV, Bingham C, Fittipaldi P, et al. TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Res. 2014;16(5):445.
  • Polzer B, Medoro G, Pasch S, et al. Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med. 2014;6(11):1371–1386.
  • Xu X, Hou Y, Yin X, et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell. 2012;148(5):886–895.
  • Klein CA, Schmidt-Kittler O, Schardt JA, et al. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci USA. 1999;96(8):4494–4499.
  • Binder V, Bartenhagen C, Okpanyi V, et al. A new workflow for whole-genome sequencing of single human cells. Hum Mutat. 2014;35(10):1260–1270.
  • Schardt JA, Meyer M, Hartmann CH, et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell. 2005;8(3):227–239.
  • Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA. 2003;100(13):7737–7742.
  • Stoecklein NH, Hosch SB, Bezler M, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell. 2008;13(5):441–453.
  • Fuhrmann C, Schmidt-Kittler O, Stoecklein NH, et al. High-resolution array comparative genomic hybridization of single micrometastatic tumor cells. Nucleic Acids Res. 2008;36(7):e39.
  • Möhlendick B, Bartenhagen C, Behrens B, et al. A robust method to analyze copy number alterations of less than 100 kb in single cells using oligonucleotide array CGH. PLoS ONE. 2013;8(6):e67031.
  • Czyż ZT, Hoffmann M, Schlimok G, et al. Reliable single cell array CGH for clinical samples. PLoS ONE. 2014;9(1):e85907.
  • Stoecklein NH, Erbersdobler A, Schmidt-Kittler O, et al. SCOMP is superior to degenerated oligonucleotide primed-polymerase chain reaction for global amplification of minute amounts of DNA from microdissected archival tissue samples. Am J Pathol. 2002;161(1):43–51.
  • Arneson N, Moreno J, Iakovlev V, et al. Comparison of whole genome amplification methods for analysis of DNA extracted from microdissected early breast lesions in formalin-fixed paraffin-embedded tissue. ISRN Oncol. 2012;2012:710692.
  • Macaulay IC, Voet T. Single cell genomics: advances and future perspectives. PLoS Genet. 2014;10(1):e1004126.
  • Magbanua MJM, Park JW. Advances in genomic characterization of circulating tumor cells. Cancer Metastasis Rev. 2014;33(2–3):757–769.
  • Lohr JG, Adalsteinsson VA, Cibulskis K, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014;32(5):479–484.
  • Sakaizawa K, Goto Y, Kiniwa Y, et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer. 2012;106(5):939–946.
  • Ni X, Zhuo M, Su Z, et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci USA. 2013;110(52):21083–21088.
  • Müller C, Holtschmidt J, Auer M, et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014;6(247):247ra101–247ra101.
  • Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009;69(7):2912–2918.
  • Pailler E, Adam J, Barthélémy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol. 2013;31(18):2273–2281.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.